Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution
This article was originally published in The Tan Sheet
Executive Summary
FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports
You may also be interested in...
Draft Guidance On Developing Drug Names Calls For Simulation Studies
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
Draft Guidance On Developing Drug Names Calls For Simulation Studies
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
OTC Firms Should Improve Monograph Compliance, Registration – CDER
CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.